| Title: |
Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: Toxicity data from the UKALL14 trial |
| Authors: |
Patel B; Kirkwood AA; Dey A; Marks DI; McMillan AK; Menne TF; Micklewright L; Patrick P; Purnell S; Rowntree CJ; Smith P; Fielding AK |
| Source: |
Leukemia, 1 January 2017 |
| Publisher Information: |
Nature Publishing Group |
| Publication Year: |
2017 |
| Collection: |
Newcastle University Library ePrints Service |
| Description: |
© 2017 Macmillan Publishers Limited, part of Springer Nature. Safety and efficacy data on pegylated asparaginase (PEG-ASP) in adult acute lymphoblastic leukaemia (ALL) induction regimens are limited. The UK National Cancer Research Institute UKALL14 trial NCT01085617 prospectively evaluated the tolerability of 1000 IU/m 2 PEG-ASP administered on days 4 and 18 as part of a five-drug induction regimen in adults aged 25-65 years with de novo ALL. Median age was 46.5 years. Sixteen of the 90 patients (median age 56 years) suffered treatment-related mortality during initial induction therapy. Eight of the 16 died of sepsis in combination with hepatotoxicity. Age and Philadelphia (Ph) status were independent variables predicting induction death >40 versus ≤40 years, odds ratio (OR) 18.5 (2.02-169.0), P=0.01; Ph- versus Ph+ disease, OR 13.60 (3.52-52.36), P40 years. It proved extremely toxic in patients with Ph+ ALL, possibly owing to interaction with imatinib. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
unknown |
| Relation: |
https://eprints.ncl.ac.uk/236185; https://eprints.ncl.ac.uk/fulltext.aspx?url=236185/D067CBFE-B9FC-4F04-A0C9-406EEFDE9337.pdf&pub_id=236185 |
| Availability: |
https://eprints.ncl.ac.uk/236185 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.82C0DFD9 |
| Database: |
BASE |